NDA 204114 · Novartis
Mekinist
Trametinib Dimethyl Sulfoxide · Oral
NovelBreakthrough therapyAccelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
May 29, 2013
Approved uses
13
Original approval plus efficacy supplements
Registered trials
16
2 Phase 3, 1 recruiting
FAERS reports
24,319
17,696 serious, 5,169 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 7, 2026.
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal...
Mechanism: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 7, 2025 Supplement 34 · Efficacy OrphanLetterLabel
- Aug 31, 2023 Supplement 29 · Efficacy · priority review OrphanLetterLabel
- Mar 16, 2023 Supplement 25 · Efficacy · priority review OrphanLabelLetter
- Jun 22, 2022 Supplement 24 · Efficacy · priority review OrphanLabelLetter
- May 27, 2022 Supplement 23 · Efficacy LetterLabel
- Jan 28, 2022 Supplement 19 · Efficacy OrphanLetterLabel
- Oct 6, 2019 Supplement 12 · Efficacy OrphanLabelLetter
- May 4, 2018 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Apr 30, 2018 Supplement 7 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jun 22, 2017 Supplement 5 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 20, 2015 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Jan 8, 2014 Supplement 1 · Efficacy · priority review Accelerated approvalOrphanLabelLetter
- May 29, 2013 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanReviewLabelOther
3 products under this application
- MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 2MG · TABLET, ORAL · Prescription · TE AB
- MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 0.5MG · TABLET, ORAL · Prescription · TE AB
- MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Trametinib Dimethyl Sulfoxide" as an intervention, any sponsor and status, largest first.
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02196181 · 280 participants (planned) · Start Sep 19, 2014 · Primary completion Mar 15, 2027
Drug: Dabrafenib Mesylate; Trametinib Dimethyl Sulfoxide · For: Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 752 sites in all
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02224781 · 267 participants · Start Sep 8, 2015 · Primary completion Sep 30, 2023
Drug: Dabrafenib Mesylate; Ipilimumab and 2 more · For: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma and 2 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 838 sites in all
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02101788 · 260 participants · Start Apr 11, 2014 · Primary completion Apr 4, 2019
Drug: Letrozole; Paclitaxel and 4 more · For: Borderline Ovarian Serous Tumor; Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma and 3 more
Sites: Huntsville, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 501 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01336634 · 177 participants · Start Aug 5, 2011 · Primary completion Oct 1, 2015
Drug: Dabrafenib; Trametinib · For: Cancer
Sites: Los Angeles, California; Orange, California; Aurora, Colorado · 50 sites in all
University of California, San FranciscoAcademic, hospital or other
NCT07110246 · 96 participants (planned) · Start Nov 7, 2025 · Primary completion Mar 31, 2032
Drug: Dabrafenib; Trametinib · For: BRAF V600 Mutation; Low-grade Glioma; Low Grade Glioma of Brain and 1 more
Sites: Birmingham, Alabama; San Francisco, California; Washington D.C., District of Columbia · 12 sites in all
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03919071 · 58 participants (planned) · Start Feb 20, 2020 · Primary completion Sep 30, 2027
Drug: Dabrafenib Mesylate; Trametinib Dimethyl Sulfoxide · For: Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma and 5 more
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 131 sites in all
- A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationActive, not recruiting
Pediatric Brain Tumor ConsortiumResearch network
NCT04201457 · 57 participants · Start Jan 17, 2020 · Primary completion Oct 1, 2026
Drug: Dabrafenib; Trametinib and 1 more · For: Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 15 sites in all
- Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT04439318 · 50 participants · Start Feb 25, 2016 · Primary completion Jun 30, 2020
Drug: Trametinib Dimethyl Sulfoxide · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm and 3 more
Sites: Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia4,116
- death3,413
- malignant neoplasm progression2,070
- rash1,764
- fatigue1,538
- nausea1,512
- diarrhoea1,308
- chills1,303
- product use in unapproved indication1,091
- vomiting1,083
- off label use873
- headache771
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 360 |
| 2014 | 628 |
| 2015 | 1,693 |
| 2016 | 1,422 |
| 2017 | 1,760 |
| 2018 | 2,350 |
| 2019 | 2,676 |
| 2020 | 2,470 |
| 2021 | 2,414 |
| 2022 | 2,233 |
| 2023 | 2,150 |
| 2024 | 1,731 |
| 2025 | 1,525 |
| 2026 | 907 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mekinist (Trametinib Dimethyl Sulfoxide)
2024 spending
$207M
Beneficiaries
2,654
14,526 claims
Per beneficiary
$77,997
$399.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $113,841,286 |
| 2021 | $136,778,622 |
| 2022 | $159,068,731 |
| 2023 | $173,398,802 |
| 2024 | $207,005,041 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
Barbato MI, Nashed J, Bradford D, et al. · Clin Cancer Res 2024 · Randomized Controlled Trial, Multicenter Study
- Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Cox DS, Allred A, Zhou Y, et al. · Clin Pharmacol Drug Dev 2015 · Clinical Trial, Phase I, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.